162 related articles for article (PubMed ID: 8493448)
1. Cytosolic levels of estrogen-regulated pS2 protein in breast cancer: correlation with tumor proliferative activity.
Correale M; Paradiso A; Abbate I; Mangia A; Dragone CD; Tedone T; Filotico R; Schittulli F; De Lena M
Tumour Biol; 1993; 14(1):30-7. PubMed ID: 8493448
[TBL] [Abstract][Full Text] [Related]
2. pS2--a new cytosolic protein recognized by monoclonal antibodies as a marker of hormone sensitivity in breast cancer.
Correale M; Abbate I; Paradiso A; Schittulli F; Dragone CD; Tedone T; Gargano G; Catino AM; Musci MD; De Lena M
Cell Biophys; 1993; 22(1-3):101-10. PubMed ID: 7889536
[TBL] [Abstract][Full Text] [Related]
3. Prediction of relapse and survival in breast cancer patients by pS2 protein status.
Foekens JA; Rio MC; Seguin P; van Putten WL; Fauque J; Nap M; Klijn JG; Chambon P
Cancer Res; 1990 Jul; 50(13):3832-7. PubMed ID: 2354435
[TBL] [Abstract][Full Text] [Related]
4. [Cytosolic pS2 levels and cellular proliferation in ER-positive and PgR-positive infiltrating ductal carcinomas of the breast].
Sánchez Salmón A; Argibay S; Arias JI; Ruibal A
Rev Esp Med Nucl; 2005; 24(3):185-90. PubMed ID: 15847785
[TBL] [Abstract][Full Text] [Related]
5. [Immunohistochemical detection of pS2 protein in paraffin sections of breast carcinoma tissue. Comparison with results of an immunoradiometry assay].
Ahr A; Scharl A; Göhring UJ; Crombach G; Stoffl M
Pathologe; 1995 Jul; 16(4):278-84. PubMed ID: 7667210
[TBL] [Abstract][Full Text] [Related]
6. PS2 in breast cancer--alternative or complementary tool to steroid receptor status? Evaluation of 446 cases.
Gion M; Mione R; Pappagallo GL; Gatti C; Nascimben O; Bari M; Leon AE; Vinante O; Bruscagnin G
Br J Cancer; 1993 Aug; 68(2):374-9. PubMed ID: 8347494
[TBL] [Abstract][Full Text] [Related]
7. Immunoradiometric detection of pS2 and total cathepsin D in primary breast cancer biopsies: their correlation with steroid receptors.
Marsigliante S; Biscozzo L; Correale M; Paradiso A; Leo G; Abbate I; Dragone CD; Storelli C
Br J Cancer; 1994 Mar; 69(3):550-4. PubMed ID: 8123486
[TBL] [Abstract][Full Text] [Related]
8. [Analysis of the cytosolic content of the pS2 protein in breast cancer].
Tamargo F; Vizoso F; Lamelas ML; Rodil A; Vérez P; Raigoso P; Mulero M; Vázquez J; Roiz C; Allende MT
Rev Esp Med Nucl; 2002 Feb; 21(1):28-33. PubMed ID: 11820999
[TBL] [Abstract][Full Text] [Related]
9. Relationship of PS2 with response to tamoxifen therapy in patients with recurrent breast cancer.
Foekens JA; Portengen H; Look MP; van Putten WL; Thirion B; Bontenbal M; Klijn JG
Br J Cancer; 1994 Dec; 70(6):1217-23. PubMed ID: 7981080
[TBL] [Abstract][Full Text] [Related]
10. Expression of pS2 estrogen-inducible protein in primary breast cancer.
Horiguchi J; Iino Y; Takei H
Oncology; 1996; 53(1):12-5. PubMed ID: 8570124
[TBL] [Abstract][Full Text] [Related]
11. [Expression of pS2 protein in breast cancer and its relationship with estrogen and progesterone receptors].
Díez Gibert O; Machuca I; Sebastián MA; Rosel P; Navarro MA
Med Clin (Barc); 1996 Jun; 107(3):90-2. PubMed ID: 8754494
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical and biochemical analysis of the oestrogen regulated protein pS2, and its relation with oestrogen receptor and progesterone receptor in breast cancer.
Detre S; King N; Salter J; MacLennan K; McKinna JA; Dowsett M
J Clin Pathol; 1994 Mar; 47(3):240-4. PubMed ID: 8163696
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of PS2 and cathepsin D in 710 human primary breast tumors: multivariate analysis.
Foekens JA; van Putten WL; Portengen H; de Koning HY; Thirion B; Alexieva-Figusch J; Klijn JG
J Clin Oncol; 1993 May; 11(5):899-908. PubMed ID: 8487052
[TBL] [Abstract][Full Text] [Related]
14. Immunoradiometric assay of pS2 protein in breast cancer cytosols.
Goussard J; Lechevrel C; Roussel G; Cren H; Bera O; Sala M
Clin Chem; 1991 Oct; 37(10 Pt 1):1759-62. PubMed ID: 1914181
[TBL] [Abstract][Full Text] [Related]
15. PS2 protein in breast carcinomas: cut-off value of estrogen-regulated expression.
Nikolić-Vukosavljević D; Grujić-Adanja G; Janković R; Nesković-Konstantinović Z; Branković-Magić M
Neoplasma; 2001; 48(1):1-6. PubMed ID: 11327531
[TBL] [Abstract][Full Text] [Related]
16. pS2 (TFF1) levels in human breast cancer tumor samples: correlation with clinical and histological prognostic markers.
Gillesby BE; Zacharewski TR
Breast Cancer Res Treat; 1999 Aug; 56(3):253-65. PubMed ID: 10573116
[TBL] [Abstract][Full Text] [Related]
17. Correlation between pS2 protein positivity, steroid receptor status and other prognostic factors in breast cancer.
Racca S; Conti G; Pietribiasi F; Stramignoni D; Tampellini M; Valetto MR; Ghezzo F; Di Carlo F
Int J Biol Markers; 1995; 10(2):87-93. PubMed ID: 7561244
[TBL] [Abstract][Full Text] [Related]
18. Expression of pS2 protein in breast cancer.
Crombach G; Ingenhorst A; Göhring UJ; Scharl A; Neuhaus W; Möbus V; Schaeffer HJ
Arch Gynecol Obstet; 1993; 253(4):183-92. PubMed ID: 8161252
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of pS2 protein and receptors for epidermal growth factor (EGF-R), insulin-like growth factor-1 (IGF-1-R) and somatostatin (SS-R) in patients with breast and ovarian cancer.
Foekens JA; van Putten WL; Portengen H; Rodenburg CJ; Reubi JC; Berns PM; Henzen-Logmans SC; van der Burg ME; Alexieva-Figusch J; Klijn JG
J Steroid Biochem Mol Biol; 1990 Dec; 37(6):815-21. PubMed ID: 2178364
[TBL] [Abstract][Full Text] [Related]
20. Cytosolic levels of TFF1/pS2 in breast cancer: Their relationship with clinical-pathological parameters and their prognostic significance.
Corte MD; Tamargo F; Alvarez A; Rodríguez JC; Vázquez J; Sánchez R; Lamelas ML; González LO; Allende MT; García-Muñiz JL; Fueyo A; Vizoso F
Breast Cancer Res Treat; 2006 Mar; 96(1):63-72. PubMed ID: 16267614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
